Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Global IP takes centre stage at the 21st Advanced Summit on Life Sciences Patents

By Karen Loudon / May 30, 2023
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in...
Read More

Cartherics to present at the 2023 BIO International Convention

By Karen Loudon / May 24, 2023
Melbourne, Australia, 24 May 2023 – Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of...
Read More

Cartherics congratulates Rasa Islam on PhD success

By Karen Loudon / May 16, 2023
Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature. Rasa’s research thesis, titled, Re-engineering the...
Read More
1 2 3 50